Regulatory approvals from FDA and EUA and growing investment and policy support from governments worldwide forecast a bright outlook for the biotech industry in the long run.

It has been an eventful year in the big pharma and biotech space, and a lot is happening in this space that biotech investors should take note of.

Recent small cap picks.

Insider buying decreased last week with insiders buying $73.83 million of stock compared to $90.85 million in the week prior. Selling also decreased with insiders selling $1.67 billion of stock last week compared to $2.18 billion in the week prior.

Bulls showed renewed backbone last week and drew a line in the sand for the bears, buying with gusto into weakness as I suggested they would.

The market has been speculating as to whether the MannKind-Sanofi partnership will lead to a full-blown merger and acquisition.